Mentor Corp. announced Wednesday that a drug it is developing in Madison to compete with the well-known and hugely successful Botox has successfully completed the first of three Phase 3 clinical trials.
….The development of PurTox stems from Mentor’s 2003 deal for an exclusive license from the Wisconsin Alumni Research Foundation for botulinum toxin technology developed at the University of Wisconsin-Madison.